The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.
Lung cancer is the leading cause of cancer-related death globally. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and surgery is still the main treatment strategy. This study will determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.
Study Type
OBSERVATIONAL
Enrollment
300
Peking University People's Hospital
Beijing, China
RECRUITINGDisease-free survival (DFS)
Time from randomization to disease recurrence or death from any cause.
Time frame: Through study completion, an average of 2 years
Overall survival (OS)
Time from randomization to death from any cause.
Time frame: Through study completion, an average of 2 years
Relationship between translational biomarkers and clinical outcome
To evaluate if the translational biomarkers can be prediction tools for the clinical outcomes.
Time frame: Through study completion, an average of 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.